ERLEC1

Across TCGA pan-cancer cohorts, ERLEC1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ERLEC1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ERLEC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ERLEC1 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where ERLEC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.687	0.928	.017	7	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LUAD	OS	Quartile	II,III,IV	0.848	0.314	.010	4	view →
UCEC	OS	Tertile	II,III,IV	0.632	1.000	.034	4	view →
HNSC	DFS	Quartile	IV	0.678	0.921	.049	2	view →
LSCC	OS	Tertile	II,III,IV	0.592	0.895	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ERLEC1–CCRCC (OS)

Open the CCRCC breakdown →